Showing 5381-5390 of 5909 results for "".
- Harbour BioMed Announces Completion of Phase 2 Study in China of HBM9036 In Patients With Moderate-to-Severe Dry Eye Diseasehttps://modernod.com/news/harbour-biomed-announces-completion-of-phase-2-study-in-china-of-hbm9036-in-patients-with-moderate-to-severe-dry-eye-disease/2476993/Harbour BioMed (HBM) announced completion of a phase 2 study in China of HBM9036 (tanfanercept), a new, investigational TNF receptor-1 fragment, in adult patients with moderate-to-severe dry eye disease (DED). The study results, combined with previous results from HBM’s partner HanAll’s clinical
- Alcon Celebrates World Sight Day, Strengthens Commitment to Enhancing Global Access to Eye Carehttps://modernod.com/news/alcon-celebrates-world-sight-day-strengthens-commitment-to-enhancing-global-access-to-eye-care/2476983/Thousands of Alcon associates worldwide are participating in activities to support the advancement of eye health in honor of World Sight Day. To celebrate the occasion, the company announced a theme for the upcoming year, “Alcon: The Official Sponsor of 20/20,” which is designed to highlight its
- On World Sight Day, Allergan Launches National Campaign to Raise Awareness of Glaucomahttps://modernod.com/news/on-world-sight-day-allergan-launches-national-campaign-to-raise-awareness-of-glaucoma/2476984/Allergan announced a national education campaign called “My Glaucoma.” The campaign is designed to help people understand the burden of living with glaucoma and empower those with the disease and their caregivers to feel comfortable speaking with their doctor about a treatment
- Neurolign Acquires of Eye Diagnostic Technology Company Neuro Kineticshttps://modernod.com/news/neurolign-acquires-of-eye-diagnostic-technology-company-neuro-kinetics/2476981/Neurolign Technologies announced the acquisition of Neuro Kinetics of Pittsburgh, Pennsylvania, a provider of clinical eye-tracking and noninvasive neurofunctional diagnostic testing, delivering neurofunctional assessments. Terms of the deal were not disc
- Study Reports High Sensitivity in Diabetic Retinopathy Screening Using Smartphones and Automated-AI in Primary-Carehttps://modernod.com/news/study-reports-high-sensitivity-in-diabetic-retinopathy-screening-using-smartphones-and-automated-ai-in-primary-care/2476982/Nearly 50% of patients with diabetes fail to get an annual eye examination done even in the US and Europe. In many countries, less than 10% of patients referred to ophthalmologists by their primary-care physicians actually complete a dilated retinal examination. Technology can play a role in empo
- Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopiahttps://modernod.com/news/orasis-pharmaceuticals-announces-csf-1-eye-drop-successfully-met-primary-endpoint-in-phase-2b-clinical-study-in-presbyopia/2476977/Orasis Pharmaceuticals announced its CSF-1 eye drop has successfully met the primary endpoint in a phase 2b clinical study in individuals with presbyopia. CSF-1 successfully demonstrated statistically sig
- Ivantis Completes Enrollment of International SPECTRUM Registry for Hydrus Microstenthttps://modernod.com/news/ivantis-completes-enrollment-of-international-spectrum-registry-for-hydrus-microstent/2476973/Ivantis announced that it has completed enrollment in its SPECTRUM, which the company calls the largest single-device registry in ophthalmology. SPECTRUM is a patient registry for the Hydrus Microstent, a microinvasive glaucoma surgery (MIGS) device to treat patients with mild to moderate
- LLamasoft Partners with Global Eye Bank, Eversighthttps://modernod.com/news/llamasoft-partners-with-global-eye-bank-eversight/2476974/LLamasoft has announced its partnership with Eversight, a nonprofit organization dedicated to restoring sight and preventing blindness through eye donation, corneal transplantation, and vision research. Eversight will utilize LLamasoft’s solutions to make data-driven decisions that more accuratel
- ProQR Announces Positive Topline Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patientshttps://modernod.com/news/proqr-announces-positive-topline-results-from-the-phase-1-2-study-of-sepofarsen-in-lca10-patients/2476975/ProQR Therapeutics announced positive topline results from the PQ-110-001 study, a phase 1/2 dose range finding, first-in-human trial of sepofarsen (QR-110) in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. “We reported toda
- Ocutrx Unveils ORLenz for Surgery Visualization Technology in ARWear Headsethttps://modernod.com/news/ocutrx-unveils-orlenz-for-surgery-visualization-technology-in-arwear-headset/2476972/Ocutrx Vision Technologies is revealing a next-generation AR headset technology for surgery visualization called the ORLenz. A prototype of this technology is being formally introduced at the American Academy of Ophthalmology 2019 Conference in San Francisco. The ORLenz is a second medical device